Asthma exacerbations, oral corticosteroid use, and increased asthma severity are associated with adverse perinatal outcomes.1 Asthma biologics have transformed the management of severe asthma (SA), but the clinical trials that served as the basis for regulatory approvals for the biologics excluded pregnant women, and data on their safety and efficacy during pregnancy are limited. Here, we present a case series on the use of benralizumab, an IL-5 receptor antagonist, in pregnant women with SA. We obtained informed consent from all patients.